Now that it appears Tandem (NASDAQ: TNDM) will live on to fight another day our attention turns to the future. The real question is can the company find a way to compete and win. Can they find that path to becoming a commercially viable insulin pump company? Now before we go any further it’s important to understand the hurdles facing every insulin pump company not named Medtronic (NYSE: MDT).
1. The insulin pump market is NOT growing fast enough nor is it large enough to support all the existing players let alone the many who want to enter the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.